Blackcurrant Seed Oil and Baby Eczema Prevention: A One-Year Difference Was Not Maintained at Two Years

DOCTOR’S NOTES · ECZEMA EVIDENCE

An eczema-prevention headline may sound like a lifelong promise when it describes a difference seen at just one age. A blackcurrant seed oil trial is a useful example for parents: a favorable finding at 12 months was not a significant difference at 24 months.

This was dietary prevention research, not a skin-cream trial

Linnamaa and colleagues’ 2010 primary report randomized 313 pregnant mothers to blackcurrant seed oil, 151, or olive oil, 162. Supplementation began during weeks 8–16 of pregnancy, continued through breastfeeding and then was given to infants until age two. Parental atopy was present in 81.7%, making this a higher-risk study population.

The primary PubMed abstract also reports lower SCORAD at 12 months. Its conclusion describes a transient reduction. The evidence does not show that established eczema was cured or that every child receiving supplementation avoided it.

Keep the time point in the claim

The one-year absolute prevalence difference was 14.3 percentage points, calculated as 47.3 minus 33.0. That calculation describes the reported comparison at one age. It must not be presented as 14.3% fewer cases for life, and the nonsignificant two-year result does not establish a lasting preventive effect.

A later nonsignificant comparison also does not prove that the groups were exactly identical. It means the study did not establish a difference at that time using the reported analysis. Both the favorable early finding and the later limit belong in a responsible summary.

Three transfers the trial cannot support

First, a regimen beginning in pregnancy is not equivalent to starting an oil after a baby develops eczema. Second, dietary supplementation is not evidence for applying the oil to inflamed skin. Third, a named study preparation and schedule do not establish that any supplement sold under a similar ingredient name will have the same effect.

The higher-risk family context matters as well. A result in a population with frequent parental atopy should not silently become a precise prediction for every family. The abstract alone does not supply enough detail for a personalized benefit-versus-risk estimate or an infant supplement recommendation.

A practical discussion for parents

Bring the full study name to the obstetric or pediatric clinician before starting a pregnancy or infant supplement. Ask whether the question is prevention, treatment of an existing rash or nutritional adequacy; each needs different evidence. A child who already has persistent eczema needs an appropriate diagnosis and care plan rather than a prevention headline repurposed as treatment advice.

For active families, keep the routine manageable and avoid adding products simply to recreate a study title. AAD eczema guidance provides the broader clinical reference. This trial did not test #003 or establish its use in babies.

Why route, formulation and skin condition also matter in a salt-bath study

Where moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.

Continue with a related question

• How to Read an Eczema Study Without Getting Misled by Percentages
• Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
• What Is SCORAD? Understanding an Eczema Severity Score

Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.